Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Participants must meet all of the following criteria:

  1. Age ≥18 years at the time of treatment initiation.
  2. Histologically or pathologically confirmed diffuse large B-cell lymphoma (DLBCL).
  3. Patients with primary refractory disease or early relapse, defined as:

     Failure to achieve complete response (CR) after at least 4 cycles of first-line induction therapy, or

     Relapse confirmed by imaging within 12 months after achieving CR following first-line therapy.
  4. Patients who plan to initiate a glofitamab-containing treatment regimen (either monotherapy or combination therapy) within 12 months after study initiation.
  5. Willing and able to comply with study follow-up and data collection requirements.

Exclusion Criteria:

* Participants meeting any of the following criteria will be excluded:

  1. Currently participating in, or planning to participate in, any interventional clinical trial.
  2. Any condition that, in the investigator's judgment, would make the patient unsuitable for participation in this study (e.g., inability to complete follow-up, safety concerns, or significant comorbidities).